Halozyme, Baxter release positive PhIII results for a much-welcomed subcutaneous Gammagard Liquid
11 July 2011
Nancy Faigen
Please Login to read the full article.
11 July 2011
Nancy Faigen
Nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Halozyme plunges, Baxter bruised on US FDA call for more HyQ safety data
- Promising Phase II subcutaneous Cinryze data in HAE to inform further trial design
- New data set Herceptin on a subcutaneous, self-administration course
- Three year study ahead for Baxter's Gammagard in Alzheimer's disease
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
